GeneDx Holdings Corp. (WGS) Gross Margin
- Gross margin · 12 months: Value 69.37%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 69.37% | Gross profit / revenue. Period ending 2026-06-30. $315.24M ÷ $454.43M × 100 ≈ 69.37% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 315.24M USD | Gross Profit |
| Revenue | 454.43M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 139.18M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $315.24M | $454.43M | $139.18M | 69.37% |
| 2026-03-31 | $307.91M | $442.68M | $134.77M | 69.56% |
| 2025-12-31 | $298.17M | $427.54M | $129.37M | 69.74% |
| 2025-09-30 | $280.11M | $402.19M | $122.08M | 69.65% |
| 2025-06-30 | $243.41M | $362.32M | $118.91M | 67.18% |
| 2025-03-31 | $215.46M | $330.14M | $114.68M | 65.26% |
| 2024-12-31 | $194.40M | $305.45M | $111.05M | 63.64% |
| 2024-09-30 | $158.95M | $267.23M | $108.28M | 59.48% |
| 2024-06-30 | $136.38M | $243.66M | $107.28M | 55.97% |
| 2024-03-31 | $112.18M | $221.85M | $109.67M | 50.57% |
| 2023-12-31 | $90.01M | $202.57M | $112.56M | 44.43% |
| 2023-09-30 | $42.93M | $206.50M | $163.57M | 20.79% |
| 2023-06-30 | $31.22M | $236.43M | $205.21M | 13.20% |
| 2023-03-31 | $-17.14M | $223.89M | $241.03M | -7.66% |
| 2022-12-31 | $-26.75M | $234.69M | $261.44M | -11.40% |
| 2022-09-30 | $-13.23M | $231.15M | $244.38M | -5.72% |
| 2022-06-30 | $-35.09M | $191.09M | $226.18M | -18.36% |
| 2022-03-31 | $-6.65M | $201.94M | $208.59M | -3.30% |
| 2021-12-31 | $-16.60M | $212.19M | $228.80M | -7.82% |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-6.58M | $213.78M | $220.36M | -3.08% |
| 2021-03-31 | $-9.81M | $196.87M | $206.68M | -4.99% |
| 2020-12-31 | $4.03M | $179.32M | $175.30M | 2.25% |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | $82.78M | $196.17M | $113.39M | 42.20% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |